Plain-English translation of NCT05062668 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial examined the iStent Inject and Inject W, tiny implantable devices designed to lower eye pressure in people with open-angle glaucoma. Researchers studied whether placing this device during cataract surgery was safe and effective over one year, compared to cataract surgery alone. The device is part of a newer, gentler approach to glaucoma surgery that aims to minimize tissue damage.
Open-angle glaucoma is a leading cause of blindness worldwide, and the only proven treatment is lowering eye pressure. Traditional glaucoma surgery can cause complications, so doctors wanted to test whether this minimally invasive device could lower pressure effectively while causing less harm to the eye.
Participants in this trial had either received cataract surgery combined with an iStent implant, or cataract surgery alone. Researchers then reviewed their medical records and eye test results over the following year to measure eye pressure, safety, and how well their vision was preserved. This was a retrospective study, meaning participants were already past their surgeries when the research was conducted.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
France
Central Hospital Saint Quentin
Enrollment target
~80 participants
Started
September 2021
Primary completion
September 2022
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.